Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HYFT
Strong SellSinkerMindWalk Holdings Corp. · Healthcare · United States · $65M · Avg Vol: $161K/d
COMPANY DESCRIPTION
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.9M | 7.4M | 7.7M | 11.2M | -9.0% | 11.3M | 14.6M | 18.0M | 26.5% |
| EPS | -0.77 | -0.74 | -0.65 | -0.22 | — | -0.24 | -0.16 | -0.12 | — |
| Shares | 25.1M | 26.9M | 46.2M | 46.7M | +86.5% | 47.0M | — | — | — |
| Debt | 5.2M | 9.9M | 9.7M | 2.5M | -21.4% | 2.6M | — | — | — |
| Equity | 41.7M | 25.7M | 17.0M | 8.5M | -41.2% | — | — | — | — |
| Op CF | -14.3M | -2.3M | -4.6M | -9.0M | — | -9.0M | — | — | — |
| Inv CF | -1.4M | -1.1M | -0.6M | 9.8M | — | — | — | — | — |
| Fin CF | -0.4M | 0.7M | 10.7M | 83.0K | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HYFT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HYFT | MindWalk Holdings Corp.(you) | $65M | 14 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
| PLRX | Pliant Therapeutics, Inc. | $69M | 12 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| INKT | MiNK Therapeutics, Inc. | $58M | 15 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| ANVS | Annovis Bio, Inc. | $73M | 12 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
| PMVP | PMV Pharmaceuticals, Inc. | $65M | 19 | Strong Sell |
| 4875.T | MediciNova, Inc. | $70M | 18 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%